You are here

Endovascular ChemoFilter to Reduce Doxorubicin Toxicity during Intra-Arterial Chemotherapy

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 4R42CA265316-02
Agency Tracking Number: R42CA265316
Amount: $1,000,000.00
Phase: Phase II
Program: STTR
Solicitation Topic Code: 102
Solicitation Number: PA20-261
Timeline
Solicitation Year: 2020
Award Year: 2023
Award Start Date (Proposal Award Date): 2023-09-01
Award End Date (Contract End Date): 2025-08-31
Small Business Information
1123 Carnforth Ct
San Jose, CA 95120-4212
United States
DUNS: 117630144
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 STEVEN HETTS
 (415) 353-1863
 steven.hetts@ucsf.edu
Business Contact
 TERILYN MOORE
Phone: (650) 714-8593
Email: teri.moore@ucsf.edu
Research Institution
 UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
 
490 ILLINOIS STREET, 4TH FLOOR BOX 0962
SAN FRANCISCO, CA 94143-2510
United States

 Nonprofit College or University
Abstract

PROJECT SUMMARYDosing of chemotherapeutics is limited by systemic toxic side effects. We are developing a new class of image-
guided temporarily deployable, endovascular catheter-based medical devices that selectively remove specific drugs from the
blood stream to reduce systemic toxicities. The proposed ChemoFilters incorporate specialized materials that bind target
drugs in situ through a variety of mechanisms. During intraarterial chemotherapy (IAC) infusion to a target organ (e.g., a solid
organ containing a tumor), excess drug not trapped in the target organ passes through to the veins draining the organ and
then is circulated to the rest of the body, causing toxicities in distant locations. By temporarily deploying a ChemoFilter in the
vein(s) draining the organ undergoing IAC, we seek to bind excess drug before it can escape to cause systemic toxicity. The
ChemoFilter would then be removed in the interventional radiology suite shortly after the IAC procedure, thus removing
excess drug from the patient. Although paired intraaterial infusion and venous filtration can theoretically be used for any drug
that has its site of therapeutic action in one location and its site of dose-limiting toxicity in another location, the most compelling
application for this technology is increasing efficacy and safety of locoregional cancer chemotherapy.Primary and metastatic liver tumors are among the top three causes of cancer death worldwide. Image-guided
transarterial chemoembolization (TACE), a form of IAC, cost-effectively increases survival in this population. Doxorubicin
(Dox) is a low-cost, highly effective, chemotherapeutic agent frequently used in IAC. Dox use is limited by systemic toxicities,
most importantly irreversible cardiac failure. Dox follows a therapeutic linear dose-response model, in which increasing dose
linearly increases tumor cell kill, providing motivation for higher-dose Dox therapy. Our initial project has yielded ChemoFilters
that can reduce Dox deposition in the heart by 46% in animal models. We seek to build upon that success by designing,
building, and testing new devices that can be more easily navigated to the hepatic veins in human patients.Prototype ChemoFilters will be modeled, built, validated in vitro for efficacy, and tested in vivo in a large animal model
for navigability in Phase I by experienced teams from Filtro, Inc and UCSF. In phase II, the optimized devices from phase I
will then be tested for efficacy and safety in a large animal model and a first-in-man safety and efficacy study in patients with
unresectable liver cancer will be planned and initiated. Achievement of these aims will create new minimally invasive medical
devices that should markedly increase the efficacy of image-guided locoregional intraarterial chemotherapy by lowering
systemic drug concentrations and reducing systemic toxicities for the usual dose of Dox as part of TACE. Completion of this
study will poise the ChemoFilter technology for a pivotal clinical trial that would assess Dox dose escalation in any given
IAC/TACE procedure to achieve better local tumor control in fewer IAC/TACE sessions.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government